Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELY.
William J HulmeElizabeth J WilliamsonAmelia C A GreenKrishnan BhaskaranHelen I McDonaldChristopher T RentschAnna SchultzeJohn TazareHelen J CurtisAlex J WalkerLaurie A TomlinsonTom M PalmerElsie M F HorneBrian MackennaCaroline E MortonAmir MehrkarJessica MorleyLouis FisherSebastian C J BaconDavid EvansPeter InglesbyGeorge HickmanSimon DavyTom WardRichard CrokerRosalind M M EggoAngel Yun WongRohini MathurKevin WingHarriet J ForbesDaniel J GrintIan J DouglasStephen J W EvansLiam SmeethChristopher BatesJonathan CockburnJohn ParryFrank HesterSam HarperJonathan A C SterneMiguel A HernánAlex J WalkerPublished in: BMJ (Clinical research ed.) (2022)
In this cohort of healthcare workers where we would not anticipate vaccine type to be related to health status, we found no substantial differences in the incidence of SARS-CoV-2 infection or covid-19 disease up to 20 weeks after vaccination. Incidence dropped sharply at 3-4 weeks after vaccination, and there were few covid-19 related hospital attendance and admission events after this period. This is in line with expected onset of vaccine induced immunity and suggests strong protection against Alpha variant covid-19 disease for both vaccines in this relatively young and healthy population of healthcare workers.
Keyphrases
- coronavirus disease
- sars cov
- healthcare
- respiratory syndrome coronavirus
- mental health
- risk factors
- public health
- emergency department
- palliative care
- gestational age
- drug induced
- oxidative stress
- diabetic rats
- risk assessment
- climate change
- high glucose
- health information
- endothelial cells
- affordable care act
- adverse drug